Neurontin and Walking disability - a phase IV clinical study of FDA data

Summary:

Walking disability is reported as a side effect among people who take Neurontin (gabapentin), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Levaquin, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Walking disability when taking Neurontin. It is created by eHealthMe based on reports of 103,969 people who have side effects when taking Neurontin from the FDA, and is updated regularly.

What is Neurontin?

Neurontin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 107,468 Neurontin users. Check the latest studies of Neurontin.

What is Walking disability?

Walking disability is found to be associated with 291 drugs and 813 conditions by eHealthMe. Check the latest studies of Walking disability.

On Jul, 17, 2026

103,969 people reported to have side effects when taking Neurontin.
Among them, 63 people (0.06%) have Walking disability.

Could Neurontin cause Walking disability?

Among these 63 people:

How long have people been on Neurontin when they have Walking disability? *

What is the gender of people who have Walking disability when taking Neurontin? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Walking disability when taking Neurontin? *

What are other drugs people take besides Neurontin? *

What are other side effects people have besides Walking disability? *

Pain In Extremity: 37 people, 58.73%
Weakness: 36 people, 57.14%
Tooth Loss: 34 people, 53.97%
Tooth Abscess (pus formation in tooth): 34 people, 53.97%
Anaemia (lack of blood): 33 people, 52.38%
Memory Loss: 31 people, 49.21%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 31 people, 49.21%
Osteonecrosis Of Jaw (death of bone of jaw): 30 people, 47.62%
Fatigue (feeling of tiredness): 30 people, 47.62%
Urinary Tract Infection: 29 people, 46.03%

What are the existing conditions these people have? *

Breast Cancer: 23 people, 36.51%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 23 people, 36.51%
Breast Cancer Metastatic: 22 people, 34.92%
Neuropathy Peripheral (surface nerve damage): 9 people, 14.29%
Complex Regional Pain Syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)): 3 people, 4.76%
Pain In Extremity: 3 people, 4.76%
Nerve Injury: 3 people, 4.76%
Stress And Anxiety: 3 people, 4.76%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 3 people, 4.76%
Weight Loss: 2 people, 3.17%

* Approximation only. Some reports may have incomplete information.

Do you take Neurontin and have Walking disability?

- Check whether Walking disability is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neurontin:

Neurontin (107,468 reports)

Browse all side effects of Neurontin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Walking disability:

Walking disability (291 drugs)

Browse all the conditions that are associated with Walking disability:

Walking disability (813 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Neurontin) and Neurontin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.